XRF SCIENTIFIC LIMITED (XRF)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

XRF - XRF SCIENTIFIC LIMITED

FNArena Sector : Mining Sector Contracting
Year End: June
GICS Industry Group : Capital Goods
Debt/EBITDA: 0.21
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.85

02 Dec
2024

-0.040

OPEN

$1.89

-2.12%

HIGH

$1.90

388,390

LOW

$1.85

OTHER COMPANIES IN THE SAME SECTOR
ALQ . ANG . ARI . C79 . CDA . CDD . DOW . EHL . GNG . IMD . IPG . IPL . LBL . LYL . MAD . MAH . MIN . MLG . MND . MSV . MYE . NWH . ORI . PRN . RAN . RCR . RDG . RUL . SGH . SRG . SXE .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 01/10 - ex-div 1.4c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx6.5
DPS All xxxxxxxxxxxxxxx3.9
Sales/Revenue xxxxxxxxxxxxxxx59.8 M
Book Value Per Share xxxxxxxxxxxxxxx39.7
Net Operating Cash Flow xxxxxxxxxxxxxxx8.1 M
Net Profit Margin xxxxxxxxxxxxxxx14.85 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx17.06 %
Return on Invested Capital xxxxxxxxxxxxxxx16.42 %
Return on Assets xxxxxxxxxxxxxxx13.28 %
Return on Equity xxxxxxxxxxxxxxx17.06 %
Return on Total Capital xxxxxxxxxxxxxxx25.63 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx2.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx15 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx12 M
Price To Book Value xxxxxxxxxxxxxxx3.38

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx1.6 M
Capex % of Sales xxxxxxxxxxxxxxx2.75 %
Cost of Goods Sold xxxxxxxxxxxxxxx35 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

26/11/2024

1

Speculative Buy

$1.75

-5.41%

Management at XRF Scientific announced the acquisition of Labfit (manufacturer of laboratory equipment) for -$1.16m with additional potential earn-outs of -$300,000.

Labfit’s products diversify XRF's exposure to sectors such as water, agriculture, and environmental testing, alongside mining.

The analysts expect the acquisition will have a modest financial impact, adding approximately 1.4% to FY25 revenue and profit forecasts on a pro forma basis.

XRF's strong balance sheet, with an estimated $10m net cash at FY25, supports further growth investments, in the broker's view.

Canaccord highlights the complementary nature of the acquisition, which could accelerate revenue growth and profitability, reinforcing the $1.75 target and Speculative Buy rating.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 4.30 cents and EPS of 7.10 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 4.50 cents and EPS of 8.20 cents.

XRF STOCK CHART